BVS Key Statistics, Chart & Performance
The current stock price of BVS is 7.65 USD. In the past month the price increased by 13%. In the past year, price decreased by -37.75%.
BVS Latest News, Press Relases and Analysis
BVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.39 | 15.50B | ||
| SOLV | SOLVENTUM CORP | 14.36 | 14.78B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.23 | 10.67B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.5 | 5.18B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.86 | 3.99B | ||
| HAE | HAEMONETICS CORP/MASS | 16.82 | 3.89B | ||
| ICUI | ICU MEDICAL INC | 18.74 | 3.68B | ||
| XRAY | DENTSPLY SIRONA INC | 7.15 | 2.25B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.03 | 1.73B | ||
| NEOG | NEOGEN CORP | 20.13 | 1.31B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.28B | ||
| EMBC | EMBECTA CORP | 4.23 | 735.22M |
Related stock screener links
About BVS
Company Profile
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Company Info
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 950
Phone: 19194746700
BIOVENTUS INC - A / BVS FAQ
Can you describe the business of BIOVENTUS INC - A?
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
What is the stock price of BIOVENTUS INC - A today?
The current stock price of BVS is 7.65 USD. The price decreased by -1.8% in the last trading session.
What is the dividend status of BIOVENTUS INC - A?
BVS does not pay a dividend.
How is the ChartMill rating for BIOVENTUS INC - A?
BVS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in BIOVENTUS INC - A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BVS.
Can you provide the number of employees for BIOVENTUS INC - A?
BIOVENTUS INC - A (BVS) currently has 950 employees.
What is the market capitalization of BVS stock?
BIOVENTUS INC - A (BVS) has a market capitalization of 632.50M USD. This makes BVS a Small Cap stock.
BVS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is a bad performer in the overall market: 81.91% of all stocks are doing better.
BVS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BVS. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health.
BVS Financial Highlights
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS increased by 51.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.39% | ||
| ROA | 1.11% | ||
| ROE | 4.71% | ||
| Debt/Equity | 1.93 |
BVS Forecast & Estimates
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 100% is expected in the next year compared to the current price of 7.65.
For the next year, analysts expect an EPS growth of 37.53% and a revenue growth 0.32% for BVS